CompletedNCT01469039
Aripiprazole Lauroxil or Placebo for Acute Schizophrenia
About this title
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
Read the official source — NCT01469039Researchers compared ALKS 9072 and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18–70Multiple countries
Understand this study
What did researchers investigate?
Researchers compared ALKS 9072 and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 83 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateDecember 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 623
- Sponsor
- Alkermes, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Malaysia, ...
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT01469039
- Official title
Show the full official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects With Acute Exacerbation of Schizophrenia
Get this study by email
Recruitment & locations
CompletedLittle Rock, United States · Springdale, United States · Cerritos, United States
78 more locations
- Garden Grove, United States
- La Habra, United States
- Oakland, United States
- Oceanside, United States
- Orange, United States
- San Diego, United States
- Washington D.C., United States
- Fort Lauderdale, United States
- Leesburg, United States
- Atlanta, United States
- Chicago, United States
- Hoffman Estates, United States
- Overland Park, United States
- Rockville, United States
- Creve Coeur, United States
- St Louis, United States
- Philadelphia, United States
- Charleston, United States
- Austin, United States
- Dallas, United States
- Burgas, Bulgaria
- Kazanlak, Bulgaria
- Novi Iskar, Bulgaria
- Pazardzhik, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Radnevo, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Stara Zagora, Bulgaria
- Targovishte, Bulgaria
- Veliko Tarnovo, Bulgaria
- Vratsa, Bulgaria
- Cheras, Malaysia
- Johor Bahru, Malaysia
- Kuala Lumpur, Malaysia
- Kuching, Malaysia
- Mariveles, Philippines
- Cebu City, Philippines
- Iloilo City, Philippines
- Mandaluyong, Philippines
- Manila, Philippines
- Pasig, Philippines
- Oradea, Romania
- Bucharest, Romania
- Craiova, Romania
- Iași, Romania
- Târgu Mureş, Romania
- Nikol’skoye, Russia
- Staritsa, Russia
- Talagi, Russia
- Khot'kovo, Russia
- Lipetsk, Russia
- Moscow, Russia
- Nizhny Novgorod, Russia
- Rostov-on-Don, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Saratov, Russia
- Stavropol, Russia
- Voronezh, Russia
- Yaroslavl, Russia
- Jeju City, South Korea
- Jeollanam-do, South Korea
- Seoul, South Korea
- Stepanivka, Ukraine
- Chernihiv, Ukraine
- Donetsk, Ukraine
- Kharkiv, Ukraine
- Kyiv, Ukraine
- Luhansk, Ukraine
- Lviv, Ukraine
- Poltava, Ukraine
- Simferopol, Ukraine
- Ternopil, Ukraine
- Uzhhorod, Ukraine
- Vinnytsia, Ukraine
- Russia
Questions about this study
What did researchers investigate?
Researchers compared ALKS 9072 and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Alkermes, Inc.
Did this study involve medication?
Yes. The study involved medication, including ALKS 9072 and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia